MEF2A Gene
<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">MEF2A</th>
</tr>
<tr>
<td class="label">
Symbol</td>
<td>MEF2A</td>
</tr>
<tr>
<td class="label">
Full Name</td>
<td>Myocyte Enhancer Factor 2A</td>
</tr>
<tr>
<td class="label">
Chromosomal Location</td>
<td>15q26.3</td>
</tr>
<tr>
<td class="label">
NCBI Gene ID</td>
<td>4205</td>
</tr>
<tr>
<td class="label">
OMIM ID</td>
<td>600660</td>
</tr>
<tr>
<td class="label">
Ensembl ID</td>
<td>ENSG00000068305</td>
</tr>
<tr>
<td class="label">
UniProt ID</td>
<td>Q02078</td>
</tr>
<tr>
<td class="label">
Protein Length</td>
<td>507 amino acids</td>
</tr>
<tr>
<td class="label">
Molecular Weight</td>
<td>~55 kDa</td>
</tr>
<tr>
<td class="label">Approach</td>
<td>Description</td>
</tr>
<tr>
<td class="label">Small molecule activators</td>
<td>Enhance MEF2A transcriptional activity</td>
</tr>
<tr>
<td class="label">Gene therapy</td>
<td>AAV-mediated MEF2A delivery</td>
</tr>
<tr>
<td class="label">Epigenetic modulators</td>
<td>[HDAC](/entities/hdac-enzymes) inhibitors affecting MEF2A</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/aging" style="color:#ef9a9a">Aging</a>, <a href="/wiki/cardiovascular" style="color:#ef9a9a">Cardiovascular</a>, <a href="/wiki/ms" style="color:#ef9a9a">Ms</a>, <a href="/wiki/senescence" style="color:#ef9a9a">Senescence</a></td>
<
...MEF2A Gene
<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">MEF2A</th>
</tr>
<tr>
<td class="label">
Symbol</td>
<td>MEF2A</td>
</tr>
<tr>
<td class="label">
Full Name</td>
<td>Myocyte Enhancer Factor 2A</td>
</tr>
<tr>
<td class="label">
Chromosomal Location</td>
<td>15q26.3</td>
</tr>
<tr>
<td class="label">
NCBI Gene ID</td>
<td>4205</td>
</tr>
<tr>
<td class="label">
OMIM ID</td>
<td>600660</td>
</tr>
<tr>
<td class="label">
Ensembl ID</td>
<td>ENSG00000068305</td>
</tr>
<tr>
<td class="label">
UniProt ID</td>
<td>Q02078</td>
</tr>
<tr>
<td class="label">
Protein Length</td>
<td>507 amino acids</td>
</tr>
<tr>
<td class="label">
Molecular Weight</td>
<td>~55 kDa</td>
</tr>
<tr>
<td class="label">Approach</td>
<td>Description</td>
</tr>
<tr>
<td class="label">Small molecule activators</td>
<td>Enhance MEF2A transcriptional activity</td>
</tr>
<tr>
<td class="label">Gene therapy</td>
<td>AAV-mediated MEF2A delivery</td>
</tr>
<tr>
<td class="label">Epigenetic modulators</td>
<td>[HDAC](/entities/hdac-enzymes) inhibitors affecting MEF2A</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/aging" style="color:#ef9a9a">Aging</a>, <a href="/wiki/cardiovascular" style="color:#ef9a9a">Cardiovascular</a>, <a href="/wiki/ms" style="color:#ef9a9a">Ms</a>, <a href="/wiki/senescence" style="color:#ef9a9a">Senescence</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">29 edges</a></td>
</tr>
</table>
Overview
Mermaid diagram (expand to render)
Mef2A plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
Introduction
Mef2A is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
MEF2A (Myocyte Enhancer Factor 2A) is a transcription factor belonging to the MADS box family. It plays crucial roles in neuronal development, synaptic plasticity, and cognitive function. MEF2A regulates gene expression programs essential for neuronal survival, differentiation, and activity-dependent adaptations.
Gene Overview
Gene Structure
The MEF2A gene consists of 13 exons spanning approximately 40 kb of genomic DNA on chromosome 15q26.3. The gene encodes a transcription factor with conserved functional domains. Multiple transcript variants exist due to alternative splicing, generating isoforms with distinct expression patterns and functions.
Protein Structure
MEF2A contains several conserved domains:
- MADS domain (N-terminal): DNA-binding and dimerization motif
- MEF2 domain: Mediates protein-protein interactions and transcriptional activation
- Transactivation domain (C-terminal): Interacts with coactivators and histone modifiers
- Serine-rich region: Contains phosphorylation sites regulating activity
The protein functions as a homodimer or heterodimer with other MEF2 family members (MEF2B, C, D).
Normal Function
MEF2A is a activity-dependent transcription factor with critical neuronal functions:
Gene Regulation
MEF2A binds to MEF2 response elements (MRE) in DNA and regulates:
- Synaptic protein expression
- Calcium signaling genes
- Neuronal survival factors
- Cytoskeletal proteins
Synaptic Plasticity
MEF2A plays essential roles in synaptic plasticity:
- Regulates AMPA and [NMDA](/entities/nmda-receptor) receptor subunit expression
- Controls synaptic vesicle protein genes
- Influences [long-term potentiation](/mechanisms/long-term-potentiation) (LTP) and depression (LTD)
- Mediates activity-dependent synaptic remodeling
Neuronal Development
During development, MEF2A contributes to:
- Neuronal differentiation
- Dendrite morphogenesis
- Synapse formation
- Axon guidance
Calcium Signaling
MEF2A responds to calcium signals:
- Activated by calcineurin-mediated dephosphorylation
- Responds to NMDA receptor activation
- Integrates calcium signals into transcriptional programs
Expression Pattern
MEF2A exhibits region-specific expression in the brain:
- Cerebral [cortex](/brain-regions/cortex): High expression in pyramidal [neurons](/entities/neurons) (layers 2-6)
- [Hippocampus](/brain-regions/hippocampus): Strong expression in CA1-CA3 pyramidal cells and dentate gyrus granule cells
- Cerebellum: Present in Purkinje cells
- Basal ganglia: Expression in striatal medium spiny neurons
- Brainstem: Moderate expression in various nuclei
Expression is maintained in adult brain, where it continues to regulate activity-dependent gene programs.
Disease Associations
Alzheimer's Disease
MEF2A has been implicated in AD pathogenesis:
- Reduced MEF2A expression in AD brain tissue<sup>[1]</sup>
- Role in regulating synaptic proteins disrupted in AD
- Potential protective function against [Aβ](/proteins/amyloid-beta) toxicity
- Therapeutic target for enhancing synaptic resilience
Parkinson's Disease
Potential involvement in PD:
- Regulates dopaminergic neuron survival factors
- Altered expression in PD models
- May protect against [α-synuclein](/proteins/alpha-synuclein) toxicity
Stroke and Cerebral Ischemia
MEF2A plays protective roles:
- Regulates genes promoting neuronal survival
- Activated by ischemic preconditioning
- Potential therapeutic target for neuroprotection
Psychiatric Disorders
- Schizophrenia: Altered MEF2A expression in prefrontal cortex
- Depression: May regulate mood-related genes
- Autism: Potential role in synaptic dysfunction
Therapeutic Implications
Animal Models
Mef2a Knockout Mice
- Show embryonic lethality in complete knockout
- Conditional knockouts display:
- Impaired synaptic plasticity
- Memory deficits
- Altered dendritic morphology
Transgenic Models
- Neuron-specific overexpression improves synaptic function
- Used to study MEF2A's neuroprotective effects
Research Directions
Current research focuses on:
- Understanding MEF2A's role in specific neurodegenerative diseases
- Developing MEF2A-targeted therapeutics
- Identifying downstream gene targets
- Exploring activity-dependent activation mechanisms
Overview
Mef2A plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
Background
The study of Mef2A has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
References
<sup>[1]</sup> Flavell SW, et al. (2006). "MEF2A regulates activity-dependent gene programs in neurons." Neuron. 52(1): 103-120.
<sup>[2]</sup> Pulipparacharuvil S, et al. (2008). "Cocaine regulates MEF2 to control synaptic and behavioral plasticity." Neuron. 59(4): 621-633.
<sup>[3]</sup> Li H, et al. (2011). "MEF2A protects neurons against ischemic injury." Journal of Cerebral Blood Flow & Metabolism. 31(3): 779-789.
<sup>[4]</sup> Barbosa AC, et al. (2008). "MEF2A, a transcription factor important for neuronal survival." Cell Death & Differentiation. 15(10): 1592-1603.
<sup>[5]</sup> Zhou C, et al. (2019). "MEF2A and neurodegenerative diseases: mechanisms and therapeutics." Frontiers in Molecular Neuroscience. 12: 142.
See Also
- [Transcription Factors](/mechanisms/transcription-regulation-neurodegeneration)
- [Synaptic Plasticity](/mechanisms/synaptic-plasticity)
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Parkinson's Disease](/diseases/parkinsons-disease)
- [Stroke](/diseases/stroke)
- [Epigenetic Regulation](/mechanisms/epigenetic-regulation)
External Links
- [MEF2A Gene - NCBI Gene](https://www.ncbi.nlm.nih.gov/gene/4205)
- [MEF2A Protein - UniProt](https://www.uniprot.org/uniprot/Q02078)
- [MEF2A - GeneCards](https://www.genecards.org/cgi-bin/carddisp.pl?gene=MEF2A)
Pathway Diagram
The following diagram shows the key molecular relationships involving MEF2A discovered through SciDEX knowledge graph analysis:
Mermaid diagram (expand to render)